Additional lawsuits filed this year in Ohio and Pennsylvania allege that the blood thinner drug Xarelto is causing serious injuries and death to patients nationwide. Xarelto has been proven to cause complications, such as: excessive bleeding, red or black stools, frequent nosebleeds, pink or brown urine, unexplained bruises, bruises that increase in size, coughing up...
Four trial dates are set for early 2017 for the consolidated multidistrict litigation (MDL) against Bayer AG and a Johnson and Johnson subsidiary regarding injuries sustained by Xarelto patients. U.S. District Judge Eldon Fallon in the Eastern District of Louisiana issued the order for trial dates of February 6, 2017 and March 13, 2017. Mississippi’s...
Many Xarelto lawsuits that have been filed against Johnson & Johnson and Bayer Corporation allege that the pharmaceutical companies failed to disclose the reality of the blood thinner’s risks and dangers. Xarelto has been prescribed as a blood thinner to treat many conditions, from nonvalvular atrial fibrillation, deep vein thrombosis, to pulmonary embolism. The favorable...
Jasnssen Pharmaceuticals, Inc. published a recent study on the safety of Xarelto, where the drug manufacturer attempted to minimize the injuries and uncontrolled bleeding that Xarelto patients are suffering globally. Over 45,000 patients participated in the study. Janssen and the marketing firm that assisted with the study concluded that almost 3 out of 100 Xarelto patients experienced...
Although the U.S. FDA approved Xarelto in 2011, many patients have experienced liver injuries and uncontrolled bleeding, resulting in severe damage and even death in some cases. In August, 2015, Canadian regulators announced an official investigation into numerous reports of liver injuries due to Xarelto use. The report states, “This issue was identified after two publications in...
Xarelto, the blockbuster anticoagulant that was approved by the FDA in 2011, has continued to come under scrutiny by parts of the medical community. Initially, the drug was approved to help reduce the risk of blood clots in patients who had undergone knee or hip replacement. Later, Xarelto was approved to help patients with deep...
MISSION HILLS, CA – Sean David Pulskamp died tragically after taking Xarelto for three months. The cause of death was listed as cardiopulmonary arrest, pulmonary embolism, deep vein thrombosis, and pulmonary hypertension. Mr. Pulskamp was only 19 years old. Growing concerns over deaths and complications from blood thinners like Xarelto are forcing leading cardiologists to...
Press Room
